Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


Emerging and investigational therapies for neuroblastoma.

Applebaum MA, Desai AV, Glade Bender JL, Cohn SL.

Expert Opin Orphan Drugs. 2017;5(4):355-368. doi: 10.1080/21678707.2017.1304212. Epub 2017 Mar 17.


Theranostics in nuclear medicine practice.

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, Essler M.

Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671. eCollection 2017. Review.


Norepinephrine Transporter as a Target for Imaging and Therapy.

Pandit-Taskar N, Modak S.

J Nucl Med. 2017 Sep;58(Suppl 2):39S-53S. doi: 10.2967/jnumed.116.186833. Review.


Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, Koo HH, Cho EJ, Lee SK, Lim DH.

J Hematol Oncol. 2017 May 16;10(1):108. doi: 10.1186/s13045-017-0477-0.


KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC.

J Clin Oncol. 2016 Jul 20;34(21):2443-51. doi: 10.1200/JCO.2015.64.9558. Epub 2016 Apr 11.


Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran F, Pearson AD, Du Y, Meller ST, Denis-Bacelar AM, Flux GD.

Nucl Med Commun. 2016 May;37(5):466-72. doi: 10.1097/MNM.0000000000000470.


Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.


Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).

Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK.

Eur J Cancer. 2015 Nov;51(16):2465-72. doi: 10.1016/j.ejca.2015.07.023. Epub 2015 Aug 5.


Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.

Kayano D, Kinuya S.

ScientificWorldJournal. 2015;2015:189135. doi: 10.1155/2015/189135. Epub 2015 Mar 22. Review.


SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.

Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK; International Society of Pediatric Oncology.

Pediatr Blood Cancer. 2015 Aug;62(8):1305-16. doi: 10.1002/pbc.25501. Epub 2015 Mar 21.


Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK.

Clin Cancer Res. 2015 Jun 15;21(12):2715-21. doi: 10.1158/1078-0432.CCR-14-3240. Epub 2015 Feb 18.


Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.

DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK.

Br J Cancer. 2015 Feb 17;112(4):644-9. doi: 10.1038/bjc.2015.12. Epub 2015 Jan 20.


Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.

Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM.

Case Rep Oncol Med. 2014;2014:341980. doi: 10.1155/2014/341980. Epub 2014 Sep 25.


Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.

Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y.

Mol Imaging Biol. 2015 Apr;17(2):284-94. doi: 10.1007/s11307-014-0783-7.


Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.


Targeted radionuclide therapy.

Ersahin D, Doddamane I, Cheng D.

Cancers (Basel). 2011 Oct 11;3(4):3838-55. doi: 10.3390/cancers3043838.


Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.

Wang SS, Hsiao R, Limpar MM, Lomahan S, Tran TA, Maloney NJ, Ikegaki N, Tang XX.

Int J Mol Med. 2014 Jan;33(1):35-42. doi: 10.3892/ijmm.2013.1545. Epub 2013 Nov 1.


Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.

Bleeker G, Schoot RA, Caron HN, de Kraker J, Hoefnagel CA, van Eck BL, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1711-7. doi: 10.1007/s00259-013-2510-z. Epub 2013 Aug 7.


Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.

Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK.

J Nucl Med. 2013 Apr;54(4):541-8. doi: 10.2967/jnumed.112.112334. Epub 2013 Feb 25.


Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM.

Pediatr Blood Cancer. 2013 Jul;60(7):1083-94. doi: 10.1002/pbc.24487. Epub 2013 Feb 15. Review.

Supplemental Content

Support Center